MedTrace Logo

Airway Effects of Tiotropium in Patients With COPD

NCT02683668 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2025-08-29

Study results available
· View outcomes & findings →

Summary

The aim of the study is to investigate the effect of tiotropium from different devices on a panel of small (IOS, MBNW, DLCO, FVC) and large airway (FEV1, PEF) responses in patients with mild-moderate COPD. Comparisons will be made between Tiotropium Handihaler 18 micrograms once daily and Tiotropium Respimat 5 micrograms once daily

Conditions

  • COPD
  • LUNG DISEASES, OBSTRUCTIVE

Interventions

COMBINATION_PRODUCT

Handihaler-Tiotropium 18 mcg untrained

We are looking at the untrained used of Handihaler

COMBINATION_PRODUCT

Handihaler-Tiotropium 18 mcg trained

We are looking at the trained use of Handihaler after 14 days treatment

COMBINATION_PRODUCT

Respimat-Tiotropium 5 mcg trained

we are looking at the trained use of Respimat after 14 days treatment

Sponsors & Collaborators

Principal Investigators

  • Omar Usmani · Imperial College London

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-01
Primary Completion
2018-01-01
Completion
2018-01-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02683668 on ClinicalTrials.gov